uBiome Appoints Dr. Peter Turnbaugh, PhD, Associate Professor of Microbiology and Immunology at University of California San Francisco, to its Scientific Advisory Board

Share Article

The leader in microbial genomics appoints professor and researcher with the G.W. Hooper Research Foundation at the University of California San Francisco to its board of scientific advisors.

“I’m thrilled to assist uBiome in continuing to develop innovative ways of measuring the microbiome and assessing the potential consequences for host health and disease." -Dr. Peter Turnbaugh, PhD

uBiome, the leader in microbial genomics, announces the addition of Dr. Peter Turnbaugh, PhD, Associate Professor of Microbiology and Immunology at UCSF, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Turnbough will bring to uBiome insight on the impact of the human gut microbiome on pharmacology and nutrition. The appointment will help uBiome continue its advancement in human microbiome research.

“Dr. Turnbaugh’s interdisciplinary microbiome research is vital to improving the practice and application of medicine, which strongly resonates with uBiome’s mission,” said Dr. Jessica Richman, PhD, co-founder and CEO of uBiome. “We are excited to welcome Dr. Turnbaugh to our scientific advisory board where his expertise will help us provide tools to improve health and quality of life.”

Dr. Turnaugh is an Associate Professor in the Department of Microbiology and Immunology with the G.W. Hooper Research Foundation at UCSF and with the Chan Zuckerberg Biohub. The Turnbaugh lab focuses on the metabolic activities of host-associated microbes in the gut in relation to nutrition and pharmacology. He is formerly a Bauer Fellow in the Faculty of Arts and Sciences Center for Systems Biology. He has won several awards including The David Kipnis Award in Biomedical Sciences in 2009 and the Young Investigator Grant for Probiotics Research in 2015.

About joining uBiome's Scientific Advisory Board, Dr. Turnbaugh said, “I’m thrilled to assist uBiome in continuing to develop innovative ways of measuring the microbiome and assessing the potential consequences for host health and disease. In particular, I hope that in the near future microbiome data will be useful in provision medicine as we begin to unravel the mechanisms linking the human gut microbiome to inter-individual variations in drug response.”

In addition to Dr. Turnbaugh, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

uBiome Public Relations
Visit website